{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=16", "query": { "condition": "Advanced Cancer", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 9795, "total_pages": 980, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T23:55:18.766Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00549328", "title": "Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Pazopanib (GW786034)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2008-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Duluth", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549328" }, { "nct_id": "NCT04852328", "title": "Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "CUE-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-12-06", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04852328" }, { "nct_id": "NCT07262619", "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "MSI-H or dMMR Advanced Solid Tumors", "MSI-H/dMMR Gastric Cancer", "MSI-H/dMMR Colorectal Cancer", "MSI-H/dMMR Gastroesophageal-junction Cancer", "Endometrial Cancer", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "EIK1005", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA® )", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-01-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 10, "location_summary": "Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262619" }, { "nct_id": "NCT01526928", "title": "Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 612, "start_date": "2012-03-27", "completion_date": "2018-08-27", "has_results": true, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 39, "location_summary": "Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526928" }, { "nct_id": "NCT05887492", "title": "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Solid Tumors, Adult", "Lung Cancer", "Lung Adenocarcinoma" ], "interventions": [ { "name": "TNG260", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tango Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2023-06-12", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 13, "location_summary": "Santa Monica, California • Denver, Colorado • Sarasota, Florida + 10 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05887492" }, { "nct_id": "NCT00496366", "title": "Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2/Neu-positive Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2007-07-23", "completion_date": "2017-03-20", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 2, "location_summary": "Hamilton, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496366" }, { "nct_id": "NCT06540066", "title": "A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Metastatic Cancer", "Metastatic Solid Tumor" ], "interventions": [ { "name": "BGB-B3227", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2024-09-11", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 5, "location_summary": "Los Angeles, California • St Louis, Missouri • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06540066" }, { "nct_id": "NCT04733495", "title": "Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Locally Advanced Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Dietary Counseling and Surveillance", "type": "BEHAVIORAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Resistance Training", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-04-19", "completion_date": "2023-02-20", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04733495" }, { "nct_id": "NCT02606461", "title": "Selinexor in Advanced Liposarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 342, "start_date": "2016-01-04", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2023-01-23", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 26, "location_summary": "Los Angeles, California • Santa Monica, California • Stanford, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02606461" }, { "nct_id": "NCT05609942", "title": "Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Systemic Mastocytosis" ], "interventions": [ { "name": "BLU-263", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-09-25", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-22T23:55:18.766Z", "location_count": 4, "location_summary": "Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609942" } ] }